# Empagliflozin (Jardiance)

*Also known as: Jardiance, Empa, BI 10773*

In bodybuilding discussions, Jardiance is considered for glucose control during GH use, less water weight and hoped-for heart or kidney benefits. Because it sends glucose into urine, users also ask whether it could affect carb-ups, muscle fullness or training fuel. Hydration and workout tolerance are practical concerns alongside blood glucose.

Educational information only — not medical advice. Modelled values are not individual measurements or dosing recommendations.

## Dosage & duration

U.S. JARDIANCE tablet label: adults

### Labeled starting / heart and kidney dose

**Product label**

- **Dose:** 10 mg
- **How often:** Once daily in the morning, with or without food
- **How long:** Ongoing treatment for the prescribed indication

Kidney function and fluid status are assessed before starting.

- [DailyMed — JARDIANCE prescribing information (January 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075) — Sections 1, 2.1–2.3, 5.1–5.3, 11 and 12: diabetes, heart failure and selected chronic kidney disease indications; 10 mg daily, 25 mg for additional glucose control; ketoacidosis, volume depletion and infection precautions; empagliflozin molecular weight 450.91 g/mol.

### Additional glucose control

**Product label**

- **Dose:** 25 mg
- **How often:** Once daily when 10 mg is tolerated and the prescriber increases it
- **How long:** Ongoing treatment with response and tolerability review

The higher dose is for additional glycemic control; it is not the standard escalation for heart or kidney protection alone.

- [DailyMed — JARDIANCE prescribing information (January 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075) — Sections 1, 2.1–2.3, 5.1–5.3, 11 and 12: diabetes, heart failure and selected chronic kidney disease indications; 10 mg daily, 25 mg for additional glucose control; ketoacidosis, volume depletion and infection precautions; empagliflozin molecular weight 450.91 g/mol.

Standalone Jardiance tablets are labeled in 10 mg and 25 mg strengths; combination products can use other strengths.

Dose-context sources checked: 2026-10-09.

## At a glance

- **Why lifters discuss it:** Glucose and water-weight management
- **The bulking question:** Carbs, glycogen and fullness
- **Practical trade-off:** Hydration and training tolerance
  Sources or review notes: [1](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075).

**Catalog evidence label (not clinical review):** Human RCT evidence

## Jardiance and metformin work differently



| Question | Metformin | Jardiance |
| --- | --- | --- |
| Glucose action | Less liver glucose output; improved insulin sensitivity | Less glucose reabsorbed by kidneys; more enters urine |
| Practical concerns | Stomach tolerance and training questions | Fluid balance, infections and workout-fuel questions |

Neither is established as better for a bulk or cut. Jardiance can cause ketoacidosis even without very high glucose.

Visual sources checked: 2026-10-09.

- [DailyMed — metformin immediate-release prescribing information (July 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc466c46-abaa-4675-aef2-4b1a1adfd912) — Sections 1, 2.1, 2.3, 5.1–5.3 and 12.3: type 2 diabetes; adult starting doses; renal assessment, lactic acidosis and B12; nonlinear absorption and plasma versus whole-blood timing. These label timings do not calibrate the selected study curve.
- [DailyMed — JARDIANCE prescribing information (January 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075) — Sections 1, 2.1–2.3, 5.1–5.3, 11 and 12: diabetes, heart failure and selected chronic kidney disease indications; 10 mg daily, 25 mg for additional glucose control; ketoacidosis, volume depletion and infection precautions; empagliflozin molecular weight 450.91 g/mol.

## Overview

## Why compare Jardiance with metformin?

Lifters discussing GH and high food intake often want better glucose control without making eating or training harder. Metformin acts mainly through liver glucose production and insulin sensitivity; Jardiance increases glucose loss in urine. The comparison therefore includes stomach tolerance, fluid balance and training—not just which one gives a lower reading.

## Could it help a cut or reduce puffiness?

Some users hope that urinary glucose loss and less water retention will make staying lean easier. The glucose-loss mechanism is real, but a quick fall in scale weight is not a measurement of fat loss. An unverified “calories removed per day” claim should not become a guaranteed allowance in a diet plan.

## What about carb-ups and muscle fullness?

Reported bodybuilding experiences differ here. Some people worry about losing workout fuel or replenishing glycogen. Some report acceptable glucose readings; another describes worse workout tolerance. These experiences do not establish a useful carb-to-dose ratio or show that changing tablet timing preserves muscle gains.

## Heart and kidney goals, with the right context

Jardiance has real benefits in defined heart-failure and chronic-kidney-disease populations. That helps explain the interest in “organ protection,” but it does not establish protection from AAS or GH exposure in a healthy lifter.

During a cut, dehydration, very low food intake and ketogenic diets are especially relevant: the label links them to ketoacidosis risk, which can occur without very high glucose. Nausea, vomiting, abdominal pain or difficult breathing need urgent medical assessment. Genital or urinary infections also deserve prompt review.

## Reference model

Published two-compartment reference

**Revision:** empagliflozin-baron-2016-reference · version 1

**Output:** empagliflozin parent: drug concentration in plasma (ng/mL).

Published tablet model with a fixed reference profile; the chart shows drug levels, not glucose or kidney protection.

This reference profile has fixed assumptions. Changing dose or schedule does not personalize the reference profile or establish a studied regimen.

- **Formulation:** Empagliflozin oral tablets in pooled phase I–III type 2 diabetes studies
- **Route:** Oral
- **Reference population:** Fixed source reference: 50-year-old non-smoking, non-Asian man with type 2 diabetes, BMI 25 kg/m² and eGFR 100 mL/min/1.73 m²
- **Input dose basis:** Milligrams of empagliflozin active drug, as declared on a tablet; no salt, volume or syringe-unit conversion.
- **Source exposure scope:** Pooled studies included 1–100 mg oral doses, predominantly 10 and 25 mg once daily. Other schedules are mathematical scenarios; the study range is not a dosing recommendation.

### Fixed assumptions

- All covariate multipliers remain at their source reference values; random effects and residual error are zero.
- Source reference laboratory covariates are held fixed, including total protein and liver enzymes; no user-specific laboratory adjustment is applied.
- CL/F, Vc/F, Q/F and Vp/F already include oral bioavailability. No extra F factor is applied.
- The source fixed absorption lag to 0.5 h and excluded concentrations sampled within the first post-dose hour.
- The implementation reproduces the pharmacokinetic component only; source glucose, HbA1c and adverse-event models are not implemented.

### Reference parameters

- **Model structure:** Two compartments with absorption
- **Apparent clearance (CL/F):** 10.6 L/hour
- **Apparent central volume (Vc/F):** 3.14 L
- **Absorption rate (ka):** 0.196 /hour
- **Absorption delay:** 0.5 hours
- **Apparent intercompartmental clearance (Q/F):** 6.34 L/hour
- **Apparent peripheral volume (Vp/F):** 70.6 L
- **Input mass conversion:** 1 mg modelled mass per mg entered

### Scope and limitations

- The fixed reference is not a personalized estimate for kidney impairment, age, sex, body size, ancestry, meal timing or interacting medicines.
- The source fixed an absorption delay and did not use first-hour samples, limiting interpretation of the earliest curve segment.
- Predicted exposure does not establish the degree of glucose lowering, weight loss, heart or kidney benefit, or freedom from ketoacidosis.

### Model sources

- [Baron et al. 2016 — empagliflozin population PK model](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014782/) — Population PK methods/results: 12,503 concentrations from 2761 patients with type 2 diabetes. Two-compartment apparent model, first-order absorption/elimination and fixed 0.5 h absorption lag. Data in the first post-dose hour were excluded. DOI 10.1007/s13300-016-0174-y.
- [Baron 2016 supplementary Table S1 — final model parameters](https://static-content.springer.com/esm/art%3A10.1007%2Fs13300-016-0174-y/MediaObjects/13300_2016_174_MOESM1_ESM.docx) — Point estimates: CL/F 10.6 L/h, Vc/F 3.14 L, Q/F 6.34 L/h, Vp/F 70.6 L, ka 0.196 per hour, ALAG1 0.500 h. All covariate multipliers and random effects fixed at the source reference. The supplement confirms ka units despite the article text typo.
- [DailyMed — JARDIANCE prescribing information (January 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075) — Sections 1, 2.1–2.3, 5.1–5.3, 11 and 12: diabetes, heart failure and selected chronic kidney disease indications; 10 mg daily, 25 mg for additional glucose control; ketoacidosis, volume depletion and infection precautions; empagliflozin molecular weight 450.91 g/mol.

## Sources and review notes

Summary source check: 2026-10-09; see source notes 1. This does not certify medical review of the whole page.

### Notes on the quick facts

- **Why lifters discuss it:** Some people consider it alongside GH use, during a cut or in hopes of longer-term health benefits.
  Source check: 2026-10-09; not a medical review.
- **The bulking question:** Users debate whether glucose lost in urine affects workout fuel; reported experiences do not settle it.
  Source check: 2026-10-09; not a medical review.
- **Practical trade-off:** Reports vary, and the label identifies volume depletion as a treatment risk.
  Source check: 2026-10-09; not a medical review.

### References

1. [DailyMed — JARDIANCE prescribing information (January 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075) — Sections 1, 2.1–2.3, 5.1–5.3, 11 and 12: diabetes, heart failure and selected chronic kidney disease indications; 10 mg daily, 25 mg for additional glucose control; ketoacidosis, volume depletion and infection precautions; empagliflozin molecular weight 450.91 g/mol.
2. [DailyMed — metformin immediate-release prescribing information (July 2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc466c46-abaa-4675-aef2-4b1a1adfd912) — Sections 1, 2.1, 2.3, 5.1–5.3 and 12.3: type 2 diabetes; adult starting doses; renal assessment, lactic acidosis and B12; nonlinear absorption and plasma versus whole-blood timing. These label timings do not calibrate the selected study curve.
3. [Baron et al. 2016 — empagliflozin population PK model](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014782/) — Population PK methods/results: 12,503 concentrations from 2761 patients with type 2 diabetes. Two-compartment apparent model, first-order absorption/elimination and fixed 0.5 h absorption lag. Data in the first post-dose hour were excluded. DOI 10.1007/s13300-016-0174-y.
4. [Baron 2016 supplementary Table S1 — final model parameters](https://static-content.springer.com/esm/art%3A10.1007%2Fs13300-016-0174-y/MediaObjects/13300_2016_174_MOESM1_ESM.docx) — Point estimates: CL/F 10.6 L/h, Vc/F 3.14 L, Q/F 6.34 L/h, Vp/F 70.6 L, ka 0.196 per hour, ALAG1 0.500 h. All covariate multipliers and random effects fixed at the source reference. The supplement confirms ka units despite the article text typo.

---

**Canonical URL:** https://anabolicplotter.com/compounds/empagliflozin/
**Methodology:** https://anabolicplotter.com/methodology/
**Plot:** https://anabolicplotter.com/plot?compound=empagliflozin